(INNF)
VADASTUXIMAB TALIRINA(INNS)
VADASTUXIMAB TALIRIN(INNC)
IMMUNOGLOBULIN G1-KAPPA, ANTI-[HOMO SAPIENS CD33 (SIALIC ACID BINDING IG-LIKE LECTIN 3,SIGLEC3, GP67, P67)] CHIMERIC MONOCLONAL ANTIBODY CONJUGATED TO THE PYRROLOBENZODIAZEPINE (PDB) DIMER SGD-1882; GAMMA1 HEAVY CHAIN (1-447) [MUS MUSCULUS VH (IGHV1- 85*01 -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -HOMO SAPIENS IGHG1*01, G1M17,1 (CH1 (118-215), HINGE (216-230), CH2 S3>C (239) (231-340), CH3 (341-445), CHS (446- 447)) (118-447)], (220-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') [MUS MUSCULUS V-KAPPA (IGKV14-111*01 -HOMO SAPIENS IGKJ4*01) [6.3.9] (1'-107') -HOMO SAPIENS IGKC*01, KM3 (108'-214')]; DIMER (226-226'':229-229'')- BISDISULFIDE; CONJUGATED, ON TWO SITE-SPECIFIC DRUG ATTACHMENT ENGINEERED CYSTEINES (C239, C239''), TO A MAXIMUM OF 2 PYRROLOBENZODIAZEPINE (PDB) DIMERS SGD- 1882, EACH VIA A CLEAVABLE (VALINE-ALANINE DIPEPTIDE AS CATHEPSINE B CLEAVAGE SITE) MALEIMIDOCAPROYL TYPE LINKER, RECOMMENDED INN: LIST 75(WHO)
VADASTUXIMABUM TALIRINUM(INN)